Lantheus Gets FDA Approval For TAUKLARIFY Tau PET Imaging Agent In Alzheimer's Disease
Lantheus Holdings said the FDA approved TAUKLARIFY (florquinitau F 18 injection, MK-6240) for brain PET imaging in adults with cognitive impairment being evaluated for Alzheimer’s disease to detect tau NFT pathology. The approval was supported by two blinded-read studies of 500+ subjects and safety data from 1,734. LNTH reported $593.3M cash as of June 30, 2026.
How this was made
The 30-second read
Why it matters
The FDA approval creates a new labeled use for LNTH’s product, potentially improving addressable demand for tau-PET imaging in Alzheimer’s evaluation workflows.
Market read
Traders can reassess LNTH’s near-term commercialization prospects and risk profile based on a first-time regulatory approval, with follow-through dependent on adoption and broader availability.
What to watch
The article notes effectiveness is not established for non-Alzheimer’s tauopathies and that broader commercial availability is still being evaluated, which can cap near-term revenue expectations.
Background
TAUKLARIFY is a tau PET imaging agent intended to detect tau neurofibrillary tangle pathology, complementing amyloid PET and other diagnostics.
Ticker impact
Lantheus said the FDA approved TAUKLARIFY (florquinitau F 18) for tau PET imaging in adults with cognitive impairment evaluated for Alzheimer’s.
Likely positive bias for the stock on approval-related positioning, followed by volatility as investors price adoption, coverage, and broader availability path.
The article is a first-report regulatory approval with clinical performance and safety summarized, but it provides no revenue guidance or timeline for broader commercialization, limiting precision on magnitude.
Market effects
Supports the tau-PET diagnostic pathway and may lift sentiment for other Alzheimer’s imaging and radiopharmaceutical developers.
Primarily US-focused due to FDA approval, with potential spillover to global imaging adoption expectations.
Could increase international interest in tau PET diagnostics, though the article only confirms US regulatory status.
Counterpoint
Approval does not guarantee rapid uptake; reimbursement, site readiness, and competitive tau tracers could slow commercialization.
Key entities
- companyLantheus Holdings, Inc.
Radiopharmaceutical company announcing FDA approval for TAUKLARIFY (florquinitau F 18) tau PET imaging in Alzheimer’s evaluation.
- drugTAUKLARIFY (florquinitau F 18 injection)
FDA-approved tau PET imaging agent for adults with cognitive impairment evaluated for Alzheimer’s disease.
- regulatorU.S. Food and Drug Administration (FDA)
Regulatory authority that approved TAUKLARIFY for the specified PET imaging indication.
